BioStock: Aptahem on the application to initiate clinical studies

Aptahem has submitted applications to the regulatory authorities and to the Central Ethics Committee in the Netherlands for permission to start a phase I clinical trial with Apta-1. According to the company the study will be initiated on schedule this year. BioStock reached out to the company’s Clinical Research Director, Suzanne Kilany, to learn more about this milestone.

Read the full interview with Suzanne Kilany at biostock.se:

https://www.biostock.se/en/2022/09/aptahem-on-the-application-to-initiate-clinical-studies/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/